Global In Vivo Pharmacology Model Market Research Report 2026

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global In Vivo Pharmacology Model Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Inflammation Animal Models
1.2.3 Pain and Neuroscience Animal Models
1.2.4 Diabetes and Metabolic Disorders Animal Models
1.2.5 Oncology Animal Models
1.2.6 Others
1.3 Market by Application
1.3.1 Global In Vivo Pharmacology Model Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Cardiovascular Diseases
1.3.3 Neurological Diseases
1.3.4 Autoimmune Diseases
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global In Vivo Pharmacology Model Market Perspective (2021–2032)
2.2 Global In Vivo Pharmacology Model Growth Trends by Region
2.2.1 Global In Vivo Pharmacology Model Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 In Vivo Pharmacology Model Historic Market Size by Region (2021–2026)
2.2.3 In Vivo Pharmacology Model Forecasted Market Size by Region (2027–2032)
2.3 In Vivo Pharmacology Model Market Dynamics
2.3.1 In Vivo Pharmacology Model Industry Trends
2.3.2 In Vivo Pharmacology Model Market Drivers
2.3.3 In Vivo Pharmacology Model Market Challenges
2.3.4 In Vivo Pharmacology Model Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top In Vivo Pharmacology Model Players by Revenue
3.1.1 Global Top In Vivo Pharmacology Model Players by Revenue (2021–2026)
3.1.2 Global In Vivo Pharmacology Model Revenue Market Share by Players (2021–2026)
3.2 Global Top In Vivo Pharmacology Model Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by In Vivo Pharmacology Model Revenue
3.4 Global In Vivo Pharmacology Model Market Concentration Ratio
3.4.1 Global In Vivo Pharmacology Model Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by In Vivo Pharmacology Model Revenue in 2025
3.5 Global Key Players of In Vivo Pharmacology Model Head Offices and Areas Served
3.6 Global Key Players of In Vivo Pharmacology Model, Products and Applications
3.7 Global Key Players of In Vivo Pharmacology Model, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 In Vivo Pharmacology Model Breakdown Data by Type
4.1 Global In Vivo Pharmacology Model Historic Market Size by Type (2021–2026)
4.2 Global In Vivo Pharmacology Model Forecasted Market Size by Type (2027–2032)
5 In Vivo Pharmacology Model Breakdown Data by Application
5.1 Global In Vivo Pharmacology Model Historic Market Size by Application (2021–2026)
5.2 Global In Vivo Pharmacology Model Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America In Vivo Pharmacology Model Market Size (2021–2032)
6.2 North America In Vivo Pharmacology Model Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America In Vivo Pharmacology Model Market Size by Country (2021–2026)
6.4 North America In Vivo Pharmacology Model Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe In Vivo Pharmacology Model Market Size (2021–2032)
7.2 Europe In Vivo Pharmacology Model Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe In Vivo Pharmacology Model Market Size by Country (2021–2026)
7.4 Europe In Vivo Pharmacology Model Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific In Vivo Pharmacology Model Market Size (2021–2032)
8.2 Asia-Pacific In Vivo Pharmacology Model Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific In Vivo Pharmacology Model Market Size by Region (2021–2026)
8.4 Asia-Pacific In Vivo Pharmacology Model Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America In Vivo Pharmacology Model Market Size (2021–2032)
9.2 Latin America In Vivo Pharmacology Model Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America In Vivo Pharmacology Model Market Size by Country (2021–2026)
9.4 Latin America In Vivo Pharmacology Model Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa In Vivo Pharmacology Model Market Size (2021–2032)
10.2 Middle East & Africa In Vivo Pharmacology Model Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa In Vivo Pharmacology Model Market Size by Country (2021–2026)
10.4 Middle East & Africa In Vivo Pharmacology Model Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 NuChem Sciences Inc
11.1.1 NuChem Sciences Inc Company Details
11.1.2 NuChem Sciences Inc Business Overview
11.1.3 NuChem Sciences Inc In Vivo Pharmacology Model Introduction
11.1.4 NuChem Sciences Inc Revenue in In Vivo Pharmacology Model Business (2021–2026)
11.1.5 NuChem Sciences Inc Recent Development
11.2 Eurofins Discovery
11.2.1 Eurofins Discovery Company Details
11.2.2 Eurofins Discovery Business Overview
11.2.3 Eurofins Discovery In Vivo Pharmacology Model Introduction
11.2.4 Eurofins Discovery Revenue in In Vivo Pharmacology Model Business (2021–2026)
11.2.5 Eurofins Discovery Recent Development
11.3 Oncodesign Services
11.3.1 Oncodesign Services Company Details
11.3.2 Oncodesign Services Business Overview
11.3.3 Oncodesign Services In Vivo Pharmacology Model Introduction
11.3.4 Oncodesign Services Revenue in In Vivo Pharmacology Model Business (2021–2026)
11.3.5 Oncodesign Services Recent Development
11.4 Jubilant Biosys
11.4.1 Jubilant Biosys Company Details
11.4.2 Jubilant Biosys Business Overview
11.4.3 Jubilant Biosys In Vivo Pharmacology Model Introduction
11.4.4 Jubilant Biosys Revenue in In Vivo Pharmacology Model Business (2021–2026)
11.4.5 Jubilant Biosys Recent Development
11.5 Pharmaron
11.5.1 Pharmaron Company Details
11.5.2 Pharmaron Business Overview
11.5.3 Pharmaron In Vivo Pharmacology Model Introduction
11.5.4 Pharmaron Revenue in In Vivo Pharmacology Model Business (2021–2026)
11.5.5 Pharmaron Recent Development
11.6 Melior Discovery
11.6.1 Melior Discovery Company Details
11.6.2 Melior Discovery Business Overview
11.6.3 Melior Discovery In Vivo Pharmacology Model Introduction
11.6.4 Melior Discovery Revenue in In Vivo Pharmacology Model Business (2021–2026)
11.6.5 Melior Discovery Recent Development
11.7 NUVISAN GmbH
11.7.1 NUVISAN GmbH Company Details
11.7.2 NUVISAN GmbH Business Overview
11.7.3 NUVISAN GmbH In Vivo Pharmacology Model Introduction
11.7.4 NUVISAN GmbH Revenue in In Vivo Pharmacology Model Business (2021–2026)
11.7.5 NUVISAN GmbH Recent Development
11.8 Porsolt
11.8.1 Porsolt Company Details
11.8.2 Porsolt Business Overview
11.8.3 Porsolt In Vivo Pharmacology Model Introduction
11.8.4 Porsolt Revenue in In Vivo Pharmacology Model Business (2021–2026)
11.8.5 Porsolt Recent Development
11.9 Sygnature Discovery
11.9.1 Sygnature Discovery Company Details
11.9.2 Sygnature Discovery Business Overview
11.9.3 Sygnature Discovery In Vivo Pharmacology Model Introduction
11.9.4 Sygnature Discovery Revenue in In Vivo Pharmacology Model Business (2021–2026)
11.9.5 Sygnature Discovery Recent Development
11.10 Aurigene Pharmaceutical Services Ltd
11.10.1 Aurigene Pharmaceutical Services Ltd Company Details
11.10.2 Aurigene Pharmaceutical Services Ltd Business Overview
11.10.3 Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Model Introduction
11.10.4 Aurigene Pharmaceutical Services Ltd Revenue in In Vivo Pharmacology Model Business (2021–2026)
11.10.5 Aurigene Pharmaceutical Services Ltd Recent Development
11.11 Reaction Biology
11.11.1 Reaction Biology Company Details
11.11.2 Reaction Biology Business Overview
11.11.3 Reaction Biology In Vivo Pharmacology Model Introduction
11.11.4 Reaction Biology Revenue in In Vivo Pharmacology Model Business (2021–2026)
11.11.5 Reaction Biology Recent Development
11.12 Addexbio
11.12.1 Addexbio Company Details
11.12.2 Addexbio Business Overview
11.12.3 Addexbio In Vivo Pharmacology Model Introduction
11.12.4 Addexbio Revenue in In Vivo Pharmacology Model Business (2021–2026)
11.12.5 Addexbio Recent Development
11.13 Paraza Pharma, Inc
11.13.1 Paraza Pharma, Inc Company Details
11.13.2 Paraza Pharma, Inc Business Overview
11.13.3 Paraza Pharma, Inc In Vivo Pharmacology Model Introduction
11.13.4 Paraza Pharma, Inc Revenue in In Vivo Pharmacology Model Business (2021–2026)
11.13.5 Paraza Pharma, Inc Recent Development
11.14 Aragen Life Sciences Ltd
11.14.1 Aragen Life Sciences Ltd Company Details
11.14.2 Aragen Life Sciences Ltd Business Overview
11.14.3 Aragen Life Sciences Ltd In Vivo Pharmacology Model Introduction
11.14.4 Aragen Life Sciences Ltd Revenue in In Vivo Pharmacology Model Business (2021–2026)
11.14.5 Aragen Life Sciences Ltd Recent Development
11.15 Dalriada
11.15.1 Dalriada Company Details
11.15.2 Dalriada Business Overview
11.15.3 Dalriada In Vivo Pharmacology Model Introduction
11.15.4 Dalriada Revenue in In Vivo Pharmacology Model Business (2021–2026)
11.15.5 Dalriada Recent Development
11.16 Biocytogen
11.16.1 Biocytogen Company Details
11.16.2 Biocytogen Business Overview
11.16.3 Biocytogen In Vivo Pharmacology Model Introduction
11.16.4 Biocytogen Revenue in In Vivo Pharmacology Model Business (2021–2026)
11.16.5 Biocytogen Recent Development
11.17 Charles River Laboratories
11.17.1 Charles River Laboratories Company Details
11.17.2 Charles River Laboratories Business Overview
11.17.3 Charles River Laboratories In Vivo Pharmacology Model Introduction
11.17.4 Charles River Laboratories Revenue in In Vivo Pharmacology Model Business (2021–2026)
11.17.5 Charles River Laboratories Recent Development
11.18 Pharmacelsu
11.18.1 Pharmacelsu Company Details
11.18.2 Pharmacelsu Business Overview
11.18.3 Pharmacelsu In Vivo Pharmacology Model Introduction
11.18.4 Pharmacelsu Revenue in In Vivo Pharmacology Model Business (2021–2026)
11.18.5 Pharmacelsu Recent Development
11.19 HitGen Inc
11.19.1 HitGen Inc Company Details
11.19.2 HitGen Inc Business Overview
11.19.3 HitGen Inc In Vivo Pharmacology Model Introduction
11.19.4 HitGen Inc Revenue in In Vivo Pharmacology Model Business (2021–2026)
11.19.5 HitGen Inc Recent Development
11.20 TCG Lifesciences
11.20.1 TCG Lifesciences Company Details
11.20.2 TCG Lifesciences Business Overview
11.20.3 TCG Lifesciences In Vivo Pharmacology Model Introduction
11.20.4 TCG Lifesciences Revenue in In Vivo Pharmacology Model Business (2021–2026)
11.20.5 TCG Lifesciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global In Vivo Pharmacology Model Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Inflammation Animal Models
Table 3. Key Players of Pain and Neuroscience Animal Models
Table 4. Key Players of Diabetes and Metabolic Disorders Animal Models
Table 5. Key Players of Oncology Animal Models
Table 6. Key Players of Others
Table 7. Global In Vivo Pharmacology Model Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 8. Global In Vivo Pharmacology Model Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 9. Global In Vivo Pharmacology Model Market Size by Region (US$ Million), 2021–2026
Table 10. Global In Vivo Pharmacology Model Market Share by Region (2021–2026)
Table 11. Global In Vivo Pharmacology Model Forecasted Market Size by Region (US$ Million), 2027–2032
Table 12. Global In Vivo Pharmacology Model Market Share by Region (2027–2032)
Table 13. In Vivo Pharmacology Model Market Trends
Table 14. In Vivo Pharmacology Model Market Drivers
Table 15. In Vivo Pharmacology Model Market Challenges
Table 16. In Vivo Pharmacology Model Market Restraints
Table 17. Global In Vivo Pharmacology Model Revenue by Players (US$ Million), 2021–2026
Table 18. Global In Vivo Pharmacology Model Market Share by Players (2021–2026)
Table 19. Global Top In Vivo Pharmacology Model Players by Tier (Tier 1, Tier 2, and Tier 3), based on In Vivo Pharmacology Model Revenue, 2025
Table 20. Ranking of Global Top In Vivo Pharmacology Model Companies by Revenue (US$ Million) in 2025
Table 21. Global 5 Largest Players Market Share by In Vivo Pharmacology Model Revenue (CR5 and HHI), 2021–2026
Table 22. Global Key Players of In Vivo Pharmacology Model, Headquarters and Area Served
Table 23. Global Key Players of In Vivo Pharmacology Model, Products and Applications
Table 24. Global Key Players of In Vivo Pharmacology Model, Date of General Availability (GA)
Table 25. Mergers and Acquisitions, Expansion Plans
Table 26. Global In Vivo Pharmacology Model Market Size by Type (US$ Million), 2021–2026
Table 27. Global In Vivo Pharmacology Model Revenue Market Share by Type (2021–2026)
Table 28. Global In Vivo Pharmacology Model Forecasted Market Size by Type (US$ Million), 2027–2032
Table 29. Global In Vivo Pharmacology Model Revenue Market Share by Type (2027–2032)
Table 30. Global In Vivo Pharmacology Model Market Size by Application (US$ Million), 2021–2026
Table 31. Global In Vivo Pharmacology Model Revenue Market Share by Application (2021–2026)
Table 32. Global In Vivo Pharmacology Model Forecasted Market Size by Application (US$ Million), 2027–2032
Table 33. Global In Vivo Pharmacology Model Revenue Market Share by Application (2027–2032)
Table 34. North America In Vivo Pharmacology Model Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 35. North America In Vivo Pharmacology Model Market Size by Country (US$ Million), 2021–2026
Table 36. North America In Vivo Pharmacology Model Market Size by Country (US$ Million), 2027–2032
Table 37. Europe In Vivo Pharmacology Model Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 38. Europe In Vivo Pharmacology Model Market Size by Country (US$ Million), 2021–2026
Table 39. Europe In Vivo Pharmacology Model Market Size by Country (US$ Million), 2027–2032
Table 40. Asia-Pacific In Vivo Pharmacology Model Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 41. Asia-Pacific In Vivo Pharmacology Model Market Size by Region (US$ Million), 2021–2026
Table 42. Asia-Pacific In Vivo Pharmacology Model Market Size by Region (US$ Million), 2027–2032
Table 43. Latin America In Vivo Pharmacology Model Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Latin America In Vivo Pharmacology Model Market Size by Country (US$ Million), 2021–2026
Table 45. Latin America In Vivo Pharmacology Model Market Size by Country (US$ Million), 2027–2032
Table 46. Middle East & Africa In Vivo Pharmacology Model Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 47. Middle East & Africa In Vivo Pharmacology Model Market Size by Country (US$ Million), 2021–2026
Table 48. Middle East & Africa In Vivo Pharmacology Model Market Size by Country (US$ Million), 2027–2032
Table 49. NuChem Sciences Inc Company Details
Table 50. NuChem Sciences Inc Business Overview
Table 51. NuChem Sciences Inc In Vivo Pharmacology Model Product
Table 52. NuChem Sciences Inc Revenue in In Vivo Pharmacology Model Business (US$ Million), 2021–2026
Table 53. NuChem Sciences Inc Recent Development
Table 54. Eurofins Discovery Company Details
Table 55. Eurofins Discovery Business Overview
Table 56. Eurofins Discovery In Vivo Pharmacology Model Product
Table 57. Eurofins Discovery Revenue in In Vivo Pharmacology Model Business (US$ Million), 2021–2026
Table 58. Eurofins Discovery Recent Development
Table 59. Oncodesign Services Company Details
Table 60. Oncodesign Services Business Overview
Table 61. Oncodesign Services In Vivo Pharmacology Model Product
Table 62. Oncodesign Services Revenue in In Vivo Pharmacology Model Business (US$ Million), 2021–2026
Table 63. Oncodesign Services Recent Development
Table 64. Jubilant Biosys Company Details
Table 65. Jubilant Biosys Business Overview
Table 66. Jubilant Biosys In Vivo Pharmacology Model Product
Table 67. Jubilant Biosys Revenue in In Vivo Pharmacology Model Business (US$ Million), 2021–2026
Table 68. Jubilant Biosys Recent Development
Table 69. Pharmaron Company Details
Table 70. Pharmaron Business Overview
Table 71. Pharmaron In Vivo Pharmacology Model Product
Table 72. Pharmaron Revenue in In Vivo Pharmacology Model Business (US$ Million), 2021–2026
Table 73. Pharmaron Recent Development
Table 74. Melior Discovery Company Details
Table 75. Melior Discovery Business Overview
Table 76. Melior Discovery In Vivo Pharmacology Model Product
Table 77. Melior Discovery Revenue in In Vivo Pharmacology Model Business (US$ Million), 2021–2026
Table 78. Melior Discovery Recent Development
Table 79. NUVISAN GmbH Company Details
Table 80. NUVISAN GmbH Business Overview
Table 81. NUVISAN GmbH In Vivo Pharmacology Model Product
Table 82. NUVISAN GmbH Revenue in In Vivo Pharmacology Model Business (US$ Million), 2021–2026
Table 83. NUVISAN GmbH Recent Development
Table 84. Porsolt Company Details
Table 85. Porsolt Business Overview
Table 86. Porsolt In Vivo Pharmacology Model Product
Table 87. Porsolt Revenue in In Vivo Pharmacology Model Business (US$ Million), 2021–2026
Table 88. Porsolt Recent Development
Table 89. Sygnature Discovery Company Details
Table 90. Sygnature Discovery Business Overview
Table 91. Sygnature Discovery In Vivo Pharmacology Model Product
Table 92. Sygnature Discovery Revenue in In Vivo Pharmacology Model Business (US$ Million), 2021–2026
Table 93. Sygnature Discovery Recent Development
Table 94. Aurigene Pharmaceutical Services Ltd Company Details
Table 95. Aurigene Pharmaceutical Services Ltd Business Overview
Table 96. Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Model Product
Table 97. Aurigene Pharmaceutical Services Ltd Revenue in In Vivo Pharmacology Model Business (US$ Million), 2021–2026
Table 98. Aurigene Pharmaceutical Services Ltd Recent Development
Table 99. Reaction Biology Company Details
Table 100. Reaction Biology Business Overview
Table 101. Reaction Biology In Vivo Pharmacology Model Product
Table 102. Reaction Biology Revenue in In Vivo Pharmacology Model Business (US$ Million), 2021–2026
Table 103. Reaction Biology Recent Development
Table 104. Addexbio Company Details
Table 105. Addexbio Business Overview
Table 106. Addexbio In Vivo Pharmacology Model Product
Table 107. Addexbio Revenue in In Vivo Pharmacology Model Business (US$ Million), 2021–2026
Table 108. Addexbio Recent Development
Table 109. Paraza Pharma, Inc Company Details
Table 110. Paraza Pharma, Inc Business Overview
Table 111. Paraza Pharma, Inc In Vivo Pharmacology Model Product
Table 112. Paraza Pharma, Inc Revenue in In Vivo Pharmacology Model Business (US$ Million), 2021–2026
Table 113. Paraza Pharma, Inc Recent Development
Table 114. Aragen Life Sciences Ltd Company Details
Table 115. Aragen Life Sciences Ltd Business Overview
Table 116. Aragen Life Sciences Ltd In Vivo Pharmacology Model Product
Table 117. Aragen Life Sciences Ltd Revenue in In Vivo Pharmacology Model Business (US$ Million), 2021–2026
Table 118. Aragen Life Sciences Ltd Recent Development
Table 119. Dalriada Company Details
Table 120. Dalriada Business Overview
Table 121. Dalriada In Vivo Pharmacology Model Product
Table 122. Dalriada Revenue in In Vivo Pharmacology Model Business (US$ Million), 2021–2026
Table 123. Dalriada Recent Development
Table 124. Biocytogen Company Details
Table 125. Biocytogen Business Overview
Table 126. Biocytogen In Vivo Pharmacology Model Product
Table 127. Biocytogen Revenue in In Vivo Pharmacology Model Business (US$ Million), 2021–2026
Table 128. Biocytogen Recent Development
Table 129. Charles River Laboratories Company Details
Table 130. Charles River Laboratories Business Overview
Table 131. Charles River Laboratories In Vivo Pharmacology Model Product
Table 132. Charles River Laboratories Revenue in In Vivo Pharmacology Model Business (US$ Million), 2021–2026
Table 133. Charles River Laboratories Recent Development
Table 134. Pharmacelsu Company Details
Table 135. Pharmacelsu Business Overview
Table 136. Pharmacelsu In Vivo Pharmacology Model Product
Table 137. Pharmacelsu Revenue in In Vivo Pharmacology Model Business (US$ Million), 2021–2026
Table 138. Pharmacelsu Recent Development
Table 139. HitGen Inc Company Details
Table 140. HitGen Inc Business Overview
Table 141. HitGen Inc In Vivo Pharmacology Model Product
Table 142. HitGen Inc Revenue in In Vivo Pharmacology Model Business (US$ Million), 2021–2026
Table 143. HitGen Inc Recent Development
Table 144. TCG Lifesciences Company Details
Table 145. TCG Lifesciences Business Overview
Table 146. TCG Lifesciences In Vivo Pharmacology Model Product
Table 147. TCG Lifesciences Revenue in In Vivo Pharmacology Model Business (US$ Million), 2021–2026
Table 148. TCG Lifesciences Recent Development
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
Table 152. Authors List of This Report


List of Figures
Figure 1. In Vivo Pharmacology Model Picture
Figure 2. Global In Vivo Pharmacology Model Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global In Vivo Pharmacology Model Market Share by Type: 2025 vs 2032
Figure 4. Inflammation Animal Models Features
Figure 5. Pain and Neuroscience Animal Models Features
Figure 6. Diabetes and Metabolic Disorders Animal Models Features
Figure 7. Oncology Animal Models Features
Figure 8. Others Features
Figure 9. Global In Vivo Pharmacology Model Market Size by Application (US$ Million), 2021–2032
Figure 10. Global In Vivo Pharmacology Model Market Share by Application: 2025 vs 2032
Figure 11. Cardiovascular Diseases Case Studies
Figure 12. Neurological Diseases Case Studies
Figure 13. Autoimmune Diseases Case Studies
Figure 14. Others Case Studies
Figure 15. In Vivo Pharmacology Model Report Years Considered
Figure 16. Global In Vivo Pharmacology Model Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 17. Global In Vivo Pharmacology Model Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 18. Global In Vivo Pharmacology Model Market Share by Region: 2025 vs 2032
Figure 19. Global In Vivo Pharmacology Model Market Share by Players in 2025
Figure 20. Global In Vivo Pharmacology Model Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 21. The Top 10 and 5 Players Market Share by In Vivo Pharmacology Model Revenue in 2025
Figure 22. North America In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. North America In Vivo Pharmacology Model Market Share by Country (2021–2032)
Figure 24. United States In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Canada In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. Europe In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. Europe In Vivo Pharmacology Model Market Share by Country (2021–2032)
Figure 28. Germany In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. France In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. U.K. In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Italy In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Russia In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Ireland In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Asia-Pacific In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Asia-Pacific In Vivo Pharmacology Model Market Share by Region (2021–2032)
Figure 36. China In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Japan In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. South Korea In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Southeast Asia In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. India In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Australia & New Zealand In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Latin America In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Latin America In Vivo Pharmacology Model Market Share by Country (2021–2032)
Figure 44. Mexico In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Brazil In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Middle East & Africa In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Middle East & Africa In Vivo Pharmacology Model Market Share by Country (2021–2032)
Figure 48. Israel In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Saudi Arabia In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. UAE In Vivo Pharmacology Model Market Size YoY Growth (US$ Million), 2021–2032
Figure 51. NuChem Sciences Inc Revenue Growth Rate in In Vivo Pharmacology Model Business (2021–2026)
Figure 52. Eurofins Discovery Revenue Growth Rate in In Vivo Pharmacology Model Business (2021–2026)
Figure 53. Oncodesign Services Revenue Growth Rate in In Vivo Pharmacology Model Business (2021–2026)
Figure 54. Jubilant Biosys Revenue Growth Rate in In Vivo Pharmacology Model Business (2021–2026)
Figure 55. Pharmaron Revenue Growth Rate in In Vivo Pharmacology Model Business (2021–2026)
Figure 56. Melior Discovery Revenue Growth Rate in In Vivo Pharmacology Model Business (2021–2026)
Figure 57. NUVISAN GmbH Revenue Growth Rate in In Vivo Pharmacology Model Business (2021–2026)
Figure 58. Porsolt Revenue Growth Rate in In Vivo Pharmacology Model Business (2021–2026)
Figure 59. Sygnature Discovery Revenue Growth Rate in In Vivo Pharmacology Model Business (2021–2026)
Figure 60. Aurigene Pharmaceutical Services Ltd Revenue Growth Rate in In Vivo Pharmacology Model Business (2021–2026)
Figure 61. Reaction Biology Revenue Growth Rate in In Vivo Pharmacology Model Business (2021–2026)
Figure 62. Addexbio Revenue Growth Rate in In Vivo Pharmacology Model Business (2021–2026)
Figure 63. Paraza Pharma, Inc Revenue Growth Rate in In Vivo Pharmacology Model Business (2021–2026)
Figure 64. Aragen Life Sciences Ltd Revenue Growth Rate in In Vivo Pharmacology Model Business (2021–2026)
Figure 65. Dalriada Revenue Growth Rate in In Vivo Pharmacology Model Business (2021–2026)
Figure 66. Biocytogen Revenue Growth Rate in In Vivo Pharmacology Model Business (2021–2026)
Figure 67. Charles River Laboratories Revenue Growth Rate in In Vivo Pharmacology Model Business (2021–2026)
Figure 68. Pharmacelsu Revenue Growth Rate in In Vivo Pharmacology Model Business (2021–2026)
Figure 69. HitGen Inc Revenue Growth Rate in In Vivo Pharmacology Model Business (2021–2026)
Figure 70. TCG Lifesciences Revenue Growth Rate in In Vivo Pharmacology Model Business (2021–2026)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit